is tirzepatide coming off the shortage list FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many FDA says shortage of Ozempic

Frequently Asked Questions Does DSIP actually induce sleep

While clinical validation of this mechanistic advantage continues to evolve, the dual-inhibition profile positions Polmacoxib as a promising therapeutic option for managing osteoarthritis

A lot of our clients pair glutathione with TRT or other therapies

Interest in weight management supplements continues to grow, particularly those associated with GLP-1-related metabolic pathways

SPL UNCLASSIFIED SECTION Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)

Lipitor had generated peak annual sales of $12.9 billion in 2006 and remained a $9+ billion product through 2011